RU2016135418A - Новый анализ для детектирования периостина человека - Google Patents
Новый анализ для детектирования периостина человека Download PDFInfo
- Publication number
- RU2016135418A RU2016135418A RU2016135418A RU2016135418A RU2016135418A RU 2016135418 A RU2016135418 A RU 2016135418A RU 2016135418 A RU2016135418 A RU 2016135418A RU 2016135418 A RU2016135418 A RU 2016135418A RU 2016135418 A RU2016135418 A RU 2016135418A
- Authority
- RU
- Russia
- Prior art keywords
- fragment
- antibody
- derivative
- atcc under
- hybridoma deposited
- Prior art date
Links
- 238000001514 detection method Methods 0.000 title 1
- 239000012634 fragment Substances 0.000 claims 25
- 210000004408 hybridoma Anatomy 0.000 claims 21
- 210000004027 cell Anatomy 0.000 claims 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 210000003527 eukaryotic cell Anatomy 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 101710199268 Periostin Proteins 0.000 claims 2
- 102100037765 Periostin Human genes 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 claims 2
- 210000004102 animal cell Anatomy 0.000 claims 2
- 238000004113 cell culture Methods 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 241000238631 Hexapoda Species 0.000 claims 1
- 101001095308 Homo sapiens Periostin Proteins 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 102000001708 Protein Isoforms Human genes 0.000 claims 1
- 108010029485 Protein Isoforms Proteins 0.000 claims 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 239000013522 chelant Substances 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 102000048431 human POSTN Human genes 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 210000001236 prokaryotic cell Anatomy 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 229910052707 ruthenium Inorganic materials 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 210000005253 yeast cell Anatomy 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6884—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
- G01N2800/202—Dermatitis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461936967P | 2014-02-07 | 2014-02-07 | |
| US61/936,967 | 2014-02-07 | ||
| PCT/US2015/014652 WO2015120171A1 (en) | 2014-02-07 | 2015-02-05 | Novel assay to detect human periostin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016135418A true RU2016135418A (ru) | 2018-03-13 |
| RU2016135418A3 RU2016135418A3 (enExample) | 2018-10-30 |
Family
ID=52574429
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016135417A RU2016135417A (ru) | 2014-02-07 | 2015-02-05 | Новый анализ для детектирования периостина человека |
| RU2016135418A RU2016135418A (ru) | 2014-02-07 | 2015-02-05 | Новый анализ для детектирования периостина человека |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016135417A RU2016135417A (ru) | 2014-02-07 | 2015-02-05 | Новый анализ для детектирования периостина человека |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10775388B2 (enExample) |
| EP (2) | EP3102951A1 (enExample) |
| JP (3) | JP2017506064A (enExample) |
| KR (2) | KR20160122756A (enExample) |
| CN (2) | CN106164675B (enExample) |
| AU (2) | AU2015214103A1 (enExample) |
| BR (2) | BR112016017926A2 (enExample) |
| CA (2) | CA2936285A1 (enExample) |
| HK (2) | HK1232290A1 (enExample) |
| MX (2) | MX2016009490A (enExample) |
| RU (2) | RU2016135417A (enExample) |
| SG (2) | SG10201806729VA (enExample) |
| TW (1) | TW201542589A (enExample) |
| WO (2) | WO2015120171A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3002761A1 (en) | 2015-11-04 | 2017-05-11 | Astrazeneca Ab | Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil-targeted therapeutic agents in eosinophilic diseases |
| JP7006599B2 (ja) * | 2016-08-10 | 2022-02-10 | 株式会社シノテスト | 試料に含まれるペリオスチンの測定試薬、ペリオスチン測定用前処理剤、ペリオスチン測定方法及びペリオスチン測定の感度の改善方法 |
| WO2018194134A1 (ja) * | 2017-04-20 | 2018-10-25 | 株式会社シノテスト | 抗ペリオスチン抗体固定化担体、ペリオスチン測定試薬、及び抗ペリオスチン抗体固定化担体における抗体の安定化方法 |
| WO2019183131A1 (en) * | 2018-03-19 | 2019-09-26 | Bioventures, Llc | Periostin antibodies and methods of using the same |
| CN109879963A (zh) * | 2019-03-15 | 2019-06-14 | 辽宁何氏医学院 | 一种抑制组织器官纤维化和新生血管形成的单克隆抗体及其制备方法和应用 |
| EP3959221A4 (en) | 2019-04-26 | 2024-01-10 | Cornell University | KLEBSIELLA VACCINE AND METHODS OF USE |
| JPWO2023127881A1 (enExample) * | 2021-12-28 | 2023-07-06 | ||
| CN115078734A (zh) * | 2022-06-15 | 2022-09-20 | 苏州方达新药开发有限公司 | 一种细胞因子融合蛋白的检测分析方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0279582A3 (en) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| GB0407315D0 (en) | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
| TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
| CN101189033B (zh) | 2005-05-30 | 2012-03-28 | 株式会社器官再生工学 | 牙齿的制造方法、牙齿的集合体及组织的制造方法 |
| CA2625664C (en) | 2005-10-21 | 2016-01-05 | Novartis Ag | Human antibodies against il13 and therapeutic uses |
| US8017119B2 (en) | 2005-12-28 | 2011-09-13 | Daiichi Sankyo Company, Ltd. | Antibody against periostin, and a pharmaceutical composition comprising it for preventing or treating a disease in which periostin is involved |
| RU2008130898A (ru) * | 2005-12-28 | 2010-02-10 | Асубио Фарма Ко., Лтд. (Jp) | Антитело против периостина и содержащая его фармацевтическая композиция для профилактики или лечения заболевания, в развитии которого участвует периостин |
| EP2168599B1 (en) | 2007-06-27 | 2016-08-10 | Osaka University | Cancer remedy containing antibody against peptide encoded by exon-17 of periostin |
| SG2014014138A (en) | 2008-03-31 | 2014-07-30 | Genentech Inc | Compositions and methods for treating and diagnosing asthma |
| JP2011516549A (ja) * | 2008-04-11 | 2011-05-26 | バイオジェン アイデック マサチューセッツ インコーポレイテッド | 抗ｉｇｆ−１ｒ抗体と他の化合物との治療的併用 |
| FR2946349B1 (fr) * | 2009-06-03 | 2013-10-04 | Synarc Sas | Sequences, anticorps, procedes et necessaires pour la detection et le dosage in vitro de la periostine, en vue du diagnostic du suivi ou du pronostic de pathologies ou de phenomenes biologiques impliquant la periostine |
| RU2737245C2 (ru) | 2010-12-16 | 2020-11-26 | Дженентек, Инк. | Способы диагностики и лечения, связанные с ингибированием тн2 |
| US8961965B2 (en) | 2011-05-18 | 2015-02-24 | Medimmune, Llc | Methods of diagnosing and treating pulmonary diseases or disorders |
| WO2012156513A1 (en) | 2011-05-18 | 2012-11-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for determining whether a subject is at risk of having or developing a chronic kidney disease |
| WO2013035799A1 (ja) | 2011-09-06 | 2013-03-14 | 株式会社シノテスト | ペリオスチンの特定領域に結合する抗体及びこれを用いたペリオスチンの測定方法 |
| JP5797148B2 (ja) | 2011-09-12 | 2015-10-21 | 富士フイルム株式会社 | コレステリック液晶性混合物、フィルム、選択反射板、積層体および合わせガラス |
| WO2013038696A1 (ja) * | 2011-09-15 | 2013-03-21 | 国立大学法人名古屋大学 | 胸膜中皮腫患者の早期発見のための分子マーカー及びその発現解析方法 |
| US9260756B2 (en) | 2012-02-24 | 2016-02-16 | Children's Hospital Medical Center | Esophageal microRNA expression profiles in eosinophilic esophagitis |
| PL2875049T3 (pl) * | 2012-07-18 | 2019-07-31 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Sposoby zapobiegania i leczenia przewlekłej choroby nerek (ckd) |
| CN105934254A (zh) * | 2014-01-27 | 2016-09-07 | 免疫医疗有限责任公司 | 作为哮喘肺中il-13活化的外周生物标志的二肽基肽酶-4（dpp4/cd26） |
-
2015
- 2015-02-05 HK HK17105816.2A patent/HK1232290A1/zh unknown
- 2015-02-05 HK HK17105868.9A patent/HK1232238A1/zh unknown
- 2015-02-05 JP JP2016545358A patent/JP2017506064A/ja active Pending
- 2015-02-05 AU AU2015214103A patent/AU2015214103A1/en not_active Abandoned
- 2015-02-05 KR KR1020167024160A patent/KR20160122756A/ko not_active Withdrawn
- 2015-02-05 MX MX2016009490A patent/MX2016009490A/es unknown
- 2015-02-05 CN CN201580007503.4A patent/CN106164675B/zh not_active Expired - Fee Related
- 2015-02-05 SG SG10201806729VA patent/SG10201806729VA/en unknown
- 2015-02-05 EP EP15706093.0A patent/EP3102951A1/en not_active Withdrawn
- 2015-02-05 US US15/106,223 patent/US10775388B2/en active Active
- 2015-02-05 MX MX2016009450A patent/MX2016009450A/es unknown
- 2015-02-05 WO PCT/US2015/014652 patent/WO2015120171A1/en not_active Ceased
- 2015-02-05 WO PCT/US2015/014671 patent/WO2015120185A1/en not_active Ceased
- 2015-02-05 CN CN201580007504.9A patent/CN106170497A/zh active Pending
- 2015-02-05 SG SG11201606322XA patent/SG11201606322XA/en unknown
- 2015-02-05 AU AU2015214089A patent/AU2015214089A1/en not_active Abandoned
- 2015-02-05 CA CA2936285A patent/CA2936285A1/en not_active Abandoned
- 2015-02-05 EP EP15706091.4A patent/EP3102601B1/en not_active Not-in-force
- 2015-02-05 KR KR1020167024163A patent/KR20160125409A/ko not_active Withdrawn
- 2015-02-05 JP JP2016544101A patent/JP6549132B2/ja not_active Expired - Fee Related
- 2015-02-05 RU RU2016135417A patent/RU2016135417A/ru not_active Application Discontinuation
- 2015-02-05 RU RU2016135418A patent/RU2016135418A/ru not_active Application Discontinuation
- 2015-02-05 CA CA2936258A patent/CA2936258A1/en not_active Abandoned
- 2015-02-05 BR BR112016017926A patent/BR112016017926A2/pt not_active IP Right Cessation
- 2015-02-05 US US15/104,502 patent/US9862762B2/en active Active
- 2015-02-05 BR BR112016017901A patent/BR112016017901A2/pt not_active Application Discontinuation
- 2015-02-06 TW TW104104194A patent/TW201542589A/zh unknown
-
2017
- 2017-11-22 US US15/821,716 patent/US20180179272A1/en not_active Abandoned
-
2019
- 2019-07-30 JP JP2019139534A patent/JP2020000236A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016135418A (ru) | Новый анализ для детектирования периостина человека | |
| JP2017506064A5 (enExample) | ||
| HRP20201634T1 (hr) | Monoklonsko protutijelo protiv interleukina-31 | |
| IL273196B2 (en) | Claudin6 antibodies and methods of treating cancer | |
| RU2017134909A (ru) | Новая форма IL33, мутировавшие формы IL33, антитела, анализы и способы их применения | |
| RU2014100111A (ru) | МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Psl Pseudomonas, И ПУТИ ИХ ПРИМЕНЕНИЯ | |
| JP2017524725A5 (enExample) | ||
| HRP20230237T1 (hr) | Anti-psma antitijela, bispecifične molekule za vezanje antigena koje vežu psma i cd3, i njihova uporaba | |
| PE20180604A1 (es) | Anticuerpos pd-l1 (que se unen al ligando 1 de muerte celular programada 1 humana) | |
| RU2018108048A (ru) | Новые анти-pd-1 антитела | |
| KR20150001728A (ko) | Ｃｄｉｍ 결합 단백질 및 이의 용도 | |
| HRP20130877T1 (hr) | Antitijela koja neutraliziraju humani citomegalovirus i njihova primjena | |
| RU2019107134A (ru) | Анти-pd-1 антитела | |
| HRP20192038T1 (hr) | Protutijela receptora anti-epidermalnog faktora rasta (egfr) | |
| RU2012137380A (ru) | Моноклональные антитела к cd44, предназначенные для применения при лечении плоскоклеточной карциномы головы и шеи | |
| US20250145705A1 (en) | Gprc5d antibody and application thereof | |
| CN112679611B (zh) | 人源化cd47抗体或其抗原结合片段及应用 | |
| FI4031569T3 (fi) | Kantasolutekijän vasta-aineet ja niiden käyttömenetelmät | |
| RU2017123022A (ru) | Гуманизованные антитела, специфичные к альфа-энолазе, и способы применения в противоопухолевой тарапии | |
| EP3724657A1 (en) | Anti-cannabidiol antibody and uses thereof | |
| RU2021128024A (ru) | Способы культивирования клеток | |
| JP2018502577A5 (enExample) | ||
| CN119176874A (zh) | 一种能够结合lilrb2的抗体或其抗原结合片段 | |
| JP2024111419A (ja) | 抗体又は抗体フラグメント | |
| PH12022552826A1 (en) | Tgfãr2 extracellular domain truncated molecule, fusion protein of tgfãr2 extracellular domain truncated molecule and anti-egfr antibody, and anti-tumor use of fusion protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20190218 |